The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
 
Jingpei Li
No Relationships to Disclose
 
Jun Liu
No Relationships to Disclose
 
Zhuoyi Li
No Relationships to Disclose
 
Fei Cui
No Relationships to Disclose
 
Yuan Zeng
No Relationships to Disclose
 
Wenhua Liang
No Relationships to Disclose
 
Hengrui Liang
No Relationships to Disclose
 
Wei Wang
No Relationships to Disclose
 
Ke Xu
No Relationships to Disclose
 
Weipeng Cai
No Relationships to Disclose
 
JunHui Fu
No Relationships to Disclose
 
Jianxing He
No Relationships to Disclose